Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The ASD Living Biology: from cell proliferation to clinical phenotype


Autism spectrum disorder (ASD) has captured the attention of scientists, clinicians and the lay public because of its uncertain origins and striking and unexplained clinical heterogeneity. Here we review genetic, genomic, cellular, postmortem, animal model, and cell model evidence that shows ASD begins in the womb. This evidence leads to a new theory that ASD is a multistage, progressive disorder of brain development, spanning nearly all of prenatal life. ASD can begin as early as the 1st and 2nd trimester with disruption of cell proliferation and differentiation. It continues with disruption of neural migration, laminar disorganization, altered neuron maturation and neurite outgrowth, disruption of synaptogenesis and reduced neural network functioning. Among the most commonly reported high-confidence ASD (hcASD) genes, 94% express during prenatal life and affect these fetal processes in neocortex, amygdala, hippocampus, striatum and cerebellum. A majority of hcASD genes are pleiotropic, and affect proliferation/differentiation and/or synapse development. Proliferation and subsequent fetal stages can also be disrupted by maternal immune activation in the 1st trimester. Commonly implicated pathways, PI3K/AKT and RAS/ERK, are also pleiotropic and affect multiple fetal processes from proliferation through synapse and neural functional development. In different ASD individuals, variation in how and when these pleiotropic pathways are dysregulated, will lead to different, even opposing effects, producing prenatal as well as later neural and clinical heterogeneity. Thus, the pathogenesis of ASD is not set at one point in time and does not reside in one process, but rather is a cascade of prenatal pathogenic processes in the vast majority of ASD toddlers. Despite this new knowledge and theory that ASD biology begins in the womb, current research methods have not provided individualized information: What are the fetal processes and early-age molecular and cellular differences that underlie ASD in each individual child? Without such individualized knowledge, rapid advances in biological-based diagnostic, prognostic, and precision medicine treatments cannot occur. Missing, therefore, is what we call ASD Living Biology. This is a conceptual and paradigm shift towards a focus on the abnormal prenatal processes underlying ASD within each living individual. The concept emphasizes the specific need for foundational knowledge of a living child’s development from abnormal prenatal beginnings to early clinical stages. The ASD Living Biology paradigm seeks this knowledge by linking genetic and in vitro prenatal molecular, cellular and neural measurements with in vivo post-natal molecular, neural and clinical presentation and progression in each ASD child. We review the first such study, which confirms the multistage fetal nature of ASD and provides the first in vitro fetal-stage explanation for in vivo early brain overgrowth. Within-child ASD Living Biology is a novel research concept we coin here that advocates the integration of in vitro prenatal and in vivo early post-natal information to generate individualized and group-level explanations, clinically useful prognoses, and precision medicine approaches that are truly beneficial for the individual infant and toddler with ASD.


Autism spectrum disorder (ASD) has captured the attention of scientists and clinicians, as well as the lay public, in part because the clinical profile is so striking [1,2,3]. Affected individuals may display reduced ability to perceive, and engage in, every day social behaviors; they may display a preoccupation with seemingly trivial aspects of the environment (e.g., a fascination with street signs or spinning objects) and show challenges in expressing themselves verbally. Furthermore, there is considerable heterogeneity in each of those domains. Some individuals with ASD attempt to make friends and have good eye contact, while others appear completely aloof; some have IQs that far exceed normal average, while others are unable to talk [4]. Despite this interest and knowledge about ASD clinical heterogeneity, the prenatal beginning stages of ASD in the vast percentage of affected children are unstudied and unknown. This is because most current approaches are unable to examine the underlying abnormal fetal processes in the child with ASD that lead to that child’s clinical and neural outcomes. Thus, the prenatal and early post-natal biological bases for the striking clinical heterogeneity remain largely a mystery and controversial. Without this understanding, “precision” medicine and treatments at the individual child level do not exist in any meaningful way.

These major gaps are due to too little knowledge of what we term ASD Living Biology: We use the term ASD Living Biology to emphasize the critical need for the field to acquire an integrated system of knowledge about an ASD child’s development from abnormal prenatal beginnings to early clinical stages, arguably the most important developmental period in ASD. To gain that knowledge requires a paradigm shift that acquires and integrates genetic and in vitro prenatal molecular, cellular and neural measurements with in vivo post-natal neural and clinical presentation and progression in each ASD child. Thus, ASD Living Biology is a research concept we coin here that advocates the integration of within-child in vitro prenatal and in vivo post-natal information to generate individualized and group level explanations, clinically useful prognoses, and effective treatments for ASD. This ASD Living Biology approach enables individualized explanations and clinically useful prognosis and treatment. Such knowledge may lead to “precision medicine” for ASD: individualized early-age prognostic and treatment approaches. To specify such a system, we must address fundamental questions: When does autism begin? What are the initial molecular, neural, and developmental perturbations and their subtypes? How is neural development altered and what are the clinical implications of these neural developmental changes? Across the past decades, the answers to these questions were largely speculative and controversial.

An attempt to answer some of these questions stemmed from our early brain overgrowth theory that posited that ASD results from a prenatal disruption of neurogenesis that generates an overabundance of cortical neurons and disrupts circuit formation and function in large-scale frontal, temporal and amygdala social and language networks [5,6,7] (Fig. 1). This theory resulted from the discovery of enlarged brain volumes in frontal and temporal cortex in many ASD toddlers and young children as evidenced from magnetic resonance imaging (MRI) [5, 8,9,10,11,12,13,14], increased cortical surface area or thickness during early-age development [15,16,17,18], increased volume of frontal axon tracts [19], accelerated and atypical head circumference growth across early life [20,21,22], and greater brain weight in ASD [23,24,25]. While it is also known that a subset of ASD have small brain size, sometimes associated with extremely rare chromosomal defects [26,27,28,29], a meta-analysis by Sacco et al. [30] of 8,310 subjects from 44 MRI and 27 head circumference studies spanning toddlerhood to adulthood finds significant brain and head circumference overgrowth in ASD compared to controls across ages; the most pronounced brain and head size increases occur at early ages.

Fig. 1

Illustration of early brain overgrowth in ASD. Brain overgrowth in the first years of life occurs in many ASD toddlers and is due to prenatal cell cycle dysregulation that causes an overabundance of cortical neurons. This is theorized to lead to disrupted neural network development and function, and ASD symptoms [5,6,7, 24, 31,32,33,34]. Unbiased, blinded stereological analyses find that young ASD male children have an average 67% more prefrontal neurons than controls [24]. Since cortical neuron generation occurs only in prenatal life in humans, this is direct evidence that ASD begins in the womb. As discussed in this review and previously [56], abnormal early brain undergrowth in toddlers with ASD may also be due to cell cycle dysregulation. Adapted from Courchesne et al. [7]

Many now hypothesize that prenatal processes, such as abnormal cell proliferation, might underlie early-age brain growth defects in ASD [5,6,7, 24, 31,32,33,34], including both ASD overgrowth and undergrowth. Mechanisms regulating cerebral cell proliferation are well understood [35], and in humans, this fetal stage occurs in the 1st and 2nd trimesters (Fig. 2) [36,37,38,39]. Disruption of proliferation can have downstream consequences for differentiation, cell fate, migration, maturation, synapse development and circuit patterns. Therefore, it is crucial to know whether disrupted development in ASD begins as early as the proliferation stage, and to know if this represents a small subset of ASD or is more generally present.

Fig. 2

Developmental timeline relevant to ASD. Schematic of prominent processes occurring during different periods of human fetal and post-natal brain development. Adapted from Lombardo et al. [127]

Here we review recent postmortem, cell model, transcriptomic, genetic, genomic systems and animal model evidence that directly speaks to this specific theory of ASD beginnings and to the general hypothesis that ASD involves disruption of multiple fetal stages. We conclude that new evidence supports a new theory that ASD is a progressive prenatal disorder that precedes and produces post-natal phenotypic heterogeneity. As such, we also conclude that a paradigm shift toward an ASD Living Biology approach is necessary to uncover the beginning stages of ASD in each living child, understand how early neurobiological processes lead to the striking clinical heterogeneity in ASD, and develop “precision” treatments at the individual child level.

ASD begins in the womb

ASD postmortem evidence

Strong evidence that ASD begins in the womb comes from observations that young ASD male children have 67% more prefrontal neurons than controls [24] (Fig. 1). Neuron overabundance is not uniform in prefrontal cortex: Neuron excess was 79% in dorsolateral and 29% in medial prefrontal cortex [24]. Moreover, the degree of neuron excess across ASD cases was heterogeneous, ranging from 12 to 106%. In four ASD cases [24], neuron excess was >83% of control average. One child had an excess of 106% and mutation of PTEN, a high-confidence ASD gene. In another study, cortex in young ASD cases had 36% more neurons than controls [40] (Table S1). Young ASD males have ~53% more von Economo neurons in frontoinsular cortex than controls [41]. Cell cycle, differentiation, and DNA damage response genes and pathways are dysregulated in prefrontal cortex at young ages in ASD, and immune gene expression is upregulated [42]. Because proliferation of cortical neurons is exponential between 10 and 20 weeks of gestation [43, 44] and does not occur postnatally, pathological neuron excess cannot be caused by post-natal events and instead indicates neural disorder in ASD has a prenatal origin, likely by the first and/or second trimester.

In ASD, neural migration and cortical laminar organization, stages that occur in second and third trimesters, are also abnormal (Fig. 2) [34, 45,46,47,48]. Patches of focal laminar disorganization and nearby clusters of mis-migrated neurons were found in prefrontal and temporal cortices in 10 of 11 young ASD cases [34]. In these cases, there was heterogeneity in cortical cell types and layers that were most disrupted. While all layers were affected, patches tended to be pronounced in layers 2, 3 and 4. Patches of cortical dysplasia could be due to somatic mutations [49]. Somatic mutations (e.g., in the PI3K/AKT/mTOR pathway) also occur in hemi-megaencephaly and intractable epilepsy and may be an important prenatal source of phenotypic heterogeneity and risk in ASD and other neurodevelopment disorders [50].

Neuropathology examination of 4-year-old to 60-year-old ASD brains shows evidence of multiregional dysregulation of neurogenesis and neuronal migration in several cases, including subcortical, periventricular, hippocampal and cerebellar heterotopias reflecting abnormal neuronal migration and multifocal cerebral dysplasias [45]. Complete removal of the subplate, which normally occurs in the third trimester, may also be disrupted in ASD [47, 51]. Reduced growth of neuronal cell size and dendritic arbors in ASD postmortem cases have long been reported [25, 52] and are now recognized as an important neuropathological attribute of ASD cortex [46]; neuron size reduction varies from −4% in occipital to −18% in prefrontal cortex [24, 40, 53].

ASD patient-derived iPS cells

To test whether disruptions in proliferation and prenatal neural developmental stages are related to early brain overgrowth in vitro in ASD, Marchetto et al [54] derived iPS cells from fibroblasts from living ASD toddlers with early brain overgrowth and from control toddlers. iPS cells were differentiated to neural progenitor cells and then neurons. ASD neural progenitor cells display excess proliferation compared to normal controls (Fig. 3a–d), and that excess proliferation was correlated with the degree of each child’s MRI-based brain overgrowth (Fig. 3e). This suggests dysregulated proliferation contributes to early brain overgrowth in ASD toddlers. Excess proliferation of iPS cells and radial glia cell stage and cell cycle acceleration were also found by Mariani et al [55] in iPSCs derived from a small sample of ASD patients with brain enlargement. In Marchetto et al. [54], ASD neural progenitors doubled in number twice as fast compared to controls due to a shorter cell cycle G1/S phase. Further, reduced β-catenin and BRN2 transcriptional activity was related to this proliferation abnormality. There was also earlier but less complete cell differentiation.

Fig. 3

Excess cell proliferation, abnormal synaptic development and reduced neural activity are associated with iPS cells of ASD toddlers with enlarged brains. a  ASD iPS cells proliferate more rapidly than control. The iPS cells from ASD and control were differentiated to NPCs. From passages 2 to 6, cells were plated at the same density and population doubling time at each passage was calculated. Results of all lines (2 clones per line) are presented as mean ± s.e.m. (*repeated measurements P = 0.02, post hoc P < 0.04). b ASD cell cycle has abnormally short G1 phase. Adherent monolayer NPCs from control and ASD iPS cells were dissociated, counted for calculation of population doubling time and prepared for cell cycle analysis. Results are presented as the time spent in each cell cycle stage (n 4, mean ± s.e.m., analysis of variance (ANOVA) P < 0.04, post hoc P < 0.04 for comparing the time spent in G1 phase in the ASD NPCs with those of the control NPCs, respectively). c Control and ASD NPCs were immunostained with 4′,6-diamidino-2- phenylindole (DAPI; blue), anti-pHH3 (green) and anti-ki67 (red) (scale bar: 200 μm). Representative images of the staining are shown. d Quantification of the percentage of Ki67+ − and Ki67+ pHH3+ −labeled cells are presented as mean ± s.e.m. (n 5; *P < 0.03 for comparing the results of the ASD with those of the control NPCs). e Greater proliferation rates in ASD were correlated with greater early brain overgrowth. Pairwise correlation between individual brain size (volume) and respective NPC cell line proliferation rates (% of Ki67-positive cells). ASD displays reduced and deviant synaptic development as shown in panels f and g.  f Representative images of synaptic processes from cells after neuronal differentiation (Map2, blue). The iPSC-derived neurons express markers for excitatory neurons, such as postsynaptic density protein 95 (PSD95, red) and vesicular glutamate transporter 1 (VGlut1, green) (scale bar: 5 μm). g Bar graphs show synaptic puncta size in ASD vs control neurons (P < 0.05 for comparing the results of the ASD with those of the control neurons), and GABA-positive neurons in all ASD-derived neurons compared with all controls (*P < 0.001). h ASD neural activity is sharply reduced. Representative image of number of spikes recorded over 10 min at 50 days of culture maturation (n = 3 wells per cell type). i  ASD neural activity is sharply reduced. Top, total number of spikes from data obtained from controls (n = 6) and ASD (n = 10) clonal lines differentiating over 30 days and controls (n = 4) and ASD (n = 9) clonal lines at 50 days after differentiation over 10 min of recording. Results are presented as mean ± s.e.m. (*P = 0.0046 for comparing the results of the ASD with control networks). Bottom, number of network bursts from wells that were able to generate bursts (10 spikes over 100 ms). Results are presented as mean ± s.e.m. (*P < 0.0001 for comparing the results of the ASD with control networks). Images adapted from Marchetto et al. [54]

Multiple subsequent fetal age processes were also abnormal in every ASD case in Marchetto et al [54]. ASD patient-derived neurons additionally displayed fewer excitatory synapses, and downregulation of multiple neurotransmitter and synapse markers including GABA receptor markers (Fig. 3f, g). With increasing age from 30 to 50 days of development, ASD-derived neural networks showed less spontaneous excitatory activity and poorly synchronized activity. By 50 days, synchronized neural bursts of activity were 6 times lower in ASD than controls (Fig. 3h, i). The ASD subject with the greatest cell proliferation and brain size has a PTEN mutation and is not intellectually disabled but has severe social communication symptoms. Mariani et al. also reported multiple disrupted fetal stages in their ASD iPSC study [55], and interestingly these included excessive synaptogenesis. Thus, ASD patient-derived iPSC studies find evidence of multiple fetal stage defects with commonality in excess proliferation and cell cycle acceleration defects, but heterogeneity in synaptogenesis effects. This points to fetal stage subtypes in ASD.

These ASD Living Biology experiments suggest that neural developmental disorder in ASD spans prenatal and early post-natal life, beginning with dysregulation of cell cycle G1/S and excess cell proliferation and ending with disrupted synaptogenesis and dysfunctional nascent neural circuit activity. Heterogeneity already exists at these early stages. Mechanisms that dysregulate proliferation may dysregulate neural differentiation, cell fate determination and maturation. The conclusion that dysregulation of prenatal cell cycle G1/S underlies excess proliferation and early brain overgrowth in these toddlers with ASD is strongly supported by these ASD patient-derived iPS cell data.

Transcriptomic evidence in living ASD toddlers points to prenatal periods

Transcriptomics of leukocytes from ASD toddlers reveal further insights into ASD Living Biology. In analyses of gene expression and MRI measures of brain size at young ages, ASD toddlers with the most abnormal expression of cell cycle hub genes had the most brain overgrowth, while those with milder cell cycle disruption had smaller than normal brain size [56]. Functional genomic analyses identified 23 candidate genes for brain maldevelopment linked to 32 upstream high-confidence ASD genes [56]. Dysregulation of cell cycle G1/S was identified as contributing, suggesting shortened G1/S in bigger ASD brains, consistent with Marchetto et al [54]. CHD8 is one of the most commonly found high-confidence ASD mutations [57, 58, 62, 66], and the analyses of a CHD8 subnetwork and altered CHD8-regulated transcript levels further confirmed the central role of genes regulating neurogenesis and cell adhesion processes in ASD brain maldevelopment [56]. Thus, in living ASD infants and toddlers, patient-derived iPS cell experiments and leukocyte transcriptomics point to dysregulation of cell cycle G1/S.

High-confidence ASD genes and prenatal development

In a small percentage of children with ASD, rare de novo gene mutations are risk factors [58,59,60,61,62,63,64,65]. Genetic information accumulated via these and many other studies enable the search for likely ASD genes and gene networks. Unraveling how these mutations affect brain development is crucial to advance understanding of how genetic, non-genetic and gene/environment interactions cause ASD and influence neural development, clinical progression, and treatment. However, new evidence shows many proposed gene associations may be “noise” [66]. Of the hundreds of potential associations, 38 genes are classified as recurrent and potentially penetrant in ASD [66]. Of these 38 genes, 31 also overlap with the 65 SFARI Level 1(S) and 2(S) ASD genes; taken together, these 72 genes are high-confidence ASD (hcASD) genes.

These 72 hcASD genes, many of which regulate gene expression, are the most penetrant genes implicated in ASD thus far. It is crucial to understand how they contribute to brain growth and function because they may point to processes central to ASD development. Previous analyses of ASD risk genes were performed when knowledge of hcASD genes was more limited [67, 68], and some of those analyses gave similar weight to both low and high-confidence genes. Thus, the developmental roles of these 72 hcASD genes may have been obscured by inclusion of low confidence genes; so further study of these hcASD genes is needed.

Here we use these 72 hcASD genes to address three central questions: When during development do hcASD genes play developmental roles? Where in the brain do they do so? What functional roles may they play? First, we addressed the “when and where” roles of these hcASD genes by leveraging the most recent BrainSpan RNA-Seq dataset ( Of the 72 genes, 3 are not detected (RPKM > 0.5) in >10% of BrainSpan samples between prenatal and up to 8 years old post-natal. Therefore, here we focus on the 69 hcASD genes that do have reliable expression levels.

Of these 69 genes, 65 (94%) are expressed (RPKM > 1) in prenatal brain development. Importantly, 47 genes (68%; green cluster in Fig. 4) have peak expression during much of prenatal development, and then are downregulated following birth. Furthermore, they display peak expression in brain regions that are abnormal in ASD, including major cerebral cortical areas, hippocampus, striatum (Fig. 4), and cerebellum. From the perspective of biological roles, these hcASD genes are largely associated with proliferation and differentiation. Many are also involved in neural migration, neurite outgrowth, and early synaptogenesis (Fig. 4). The remaining 22 (32%) of the hcASD genes start to increase in expression levels during the 3rd trimester and the first several years of post-natal life (Fig. 4; purple cluster). They also express in multiple, widespread brain systems known to be abnormal in ASD (Fig. 4).

Fig. 4

The majority of hcASD genes show peak expression during prenatal life in different brain regions. Heatmaps demonstrate the developmental expression patterns (x-axis) of 69 hcASD genes (y-axis) in different brain regions in prenatal and post-natal development. In the large neocortex heatmap, hierarchical clustering of neocortex developmental transcriptome reveals two main clusters of genes, one cluster displayed in green and the other in purple (see y-axis of heatmap). Proliferation and neurogenesis hcASD genes make the largest contribution to the green cluster, and synapse development and function hcASD genes make the largest contribution to the purple cluster; see the two pie charts on the far left. This clustering pattern is present across different neocortex regions and, to a lesser degree, in hippocampus and striatum (see green and purple hcASD gene cluster patterns on y-axis of the other six heatmaps). FC: frontal cortex, Hippo: Hippocampus, OC: occipital cortex, PC: parietal cortex, Str: striatum, TC: temporal cortex.

Second, we addressed “what” developmental role all 72 hcASD genes play, and found studies that support involvement of 58 out of 72 hcASD genes in at least one of the four main brain development processes including proliferation/neurogenesis, cell fate/migration, neurite outgrowth, and spine development/synaptogenesis/synapse function (Table S2). Of these 58 hcASD genes, 33 (57%) hcASD genes are involved in cell proliferation and/or neurogenesis, while 34 (59%) are involved in spine development, synaptogenesis, and/or synapse function (Fig. 5). Importantly, our analysis underscores a crucial feature shared by the majority of hcASD genes, which is functional pleiotropy. Indeed, 36 out of 58 (62%) hcASD genes are involved in multiple major developmental processes (Fig. 5). While hcASD genes have been historically described to play primary roles in synaptic development and function, it is becoming increasingly clear that this view may represent only a partial understanding of how they contribute to ASD pathophysiology, which begins earlier during development. For example, MECP2 is known as critical player for synapse development and function of GABA-releasing neurons [69, 70]; however, its involvement spans early stages of cortical cell proliferation (likely enhanced proliferation in ASD) [71, 72, 73], neurogenesis and neural migration [73, 74], and neurite outgrowth [75]. SHANK3, a prototypical ASD gene coding for a postsynaptic scaffolding protein in excitatory synapses [76], also contributes to neurogenesis and morphogenesis during early brain development [77].

Fig. 5

Distribution of 58 hcASD genes in four main categories of neural development. Functional annotation could be found for 58 hcASD genes based on a manual literature search. Most highly penetrant ASD genes are pleiotropic, being involved in multiple stages of brain development. The small pie-charts in each region indicate the percentage of genes in green and purple clusters from Fig. 4. The gray color in pie-charts represents percentage of genes with no strong expression level in fetal and early post-natal periods. A gene is marked by an asterisk  (*) if its function was inferred from evidence in adult neural stem cells, embryonic or hematopoietic stem cells, central nervous system other than brain, or, for one gene, cancer (see Table S2 for details and references).

While our analysis highlights the roles of several hcASD genes, it is expected that further work will continue to propose and validate new genes. For example, a recent machine learning approach leveraged previously implicated genes to generate predictions of plausible new autism risk genes [78]. They further demonstrated that these genes converge on fetal and early infancy stages, and were involved in processes including cell cycle, embryogenesis,  morphogenesis, axonogenesis and synaptogenesis [78]. Furthermore, these genes also affect multiple brain structures, and are implicated in G1/S, RAS/ERK-PI3K/AKT signaling, and chromatin remodeling.

In summary, our analyses of hcASD genes (Fig. 4) and emerging work on newly predicted ASD risk genes highlight two major human neural development epochs. First, these genes are highly active during early fetal stages of cell proliferation, differentiation, migration and early organization. Second, they impact late fetal generation of synapses and functional assemblies that continue on through birth and impact the early experience and learning years. Thus, hcASD gene evidence dovetails neatly with ASD patient-derived iPS cell and leukocyte transcriptomic evidence in ASD toddlers, and ASD postmortem evidence reviewed above.

Pleiotropic common pathways implicated in ASD

Among the hcASD genes, at least 48 (67%) genes are involved in gene regulation including chromatin structure, transcription, translation, and post-translation stages. This suggests that perturbations of gene regulation contribute to ASD. Consistently, studies on hcASD genes and iPSC-derived ASD neurons highlight signaling pathways that are commonly disrupted, such as PI3K/AKT [79, 80], RAS/ERK [79, 80, 82, 83], WNT and β-catenin [57, 83, 84]. These signaling pathways are highly interconnected with crosstalk and convergence points (Fig. 6) that can vary based on the cell context and strength of input signal [85,86,87]. In neural development, these pathways are crucial in different fetal and early post-natal stages (Fig. 6; Table 1), suggesting that the pleiotropic concept can be extended from genes to molecular pathways.

Fig. 6

The RAS/ERK, PI3K/AKT, WNT and β-catenin signaling pathways are involved in different stages of brain development and are commonly disrupted in ASD. The schematic on the left indicates that these signaling pathways are highly interconnected and modulate different aspects of brain development. For this illustration, the pathways are simplified and some intermediate genes are not shown. In the table on the right, a plus sign  (+) for each pathway indicates that its dysregulation has been reported in the corresponding fetal developmental stages based on studies on either hcASD genes, ASD-derived neurons, or both (double plus signs).

Table 1 Examples of hcASD genes that converge on and disrupt RAS/ERK, PI3K/AKT, WNT and β-catenin signaling pathways

Dysregulation of proliferation and neurogenesis

Multiple ASD risk factors, including PTEN, MECP2, CHD8, ARID1B, ERBIN, and the 16p11.2 locus, link ASD to the disruption of neuron production through the PI3K/AKT, RAS/ERK, WNT and β-catenin pathways (Table 1). In precursor and radial glial cells (RGCs), upregulation of PI3K/AKT, WNT and β-catenin or downregulation of RAS/ERK leads to elevated proliferation [86, 88, 89]. The role of these pathways reverses in intermediate progenitor cells (IPCs). Activity of β-catenin (downstream of PI3K/AKT and WNT, Fig. 6) enhances premature differentiation of neurons [88], while activity of RAS/ERK reduces neurogenesis of IPCs and increases astrogenesis [90]. During human brain development, precursors differentiate into neurons first and glial cells later [91]. Therefore, dysregulation of proliferating precursor cells will perturb the number of generated neurons as well as the balance between neurogenesis and gliogenesis in the developing brain. One of the primary mechanisms that regulate neuroprogenitor divisions is the rate of cell cycle progression, particularly G1/S transition time [92, 93]. Studies on CHD8 and iPS-derived ASD neurons indicate the dysregulation of proliferation and macrocephaly in ASD could be linked to the disruption of these signaling pathways and shortened G1/S transition[54, 55, 57, 94, 183, 192, 193]. Importantly, the induced proliferation by the signaling pathways can result in either a thicker or thinner cortex in mice models depending on the strength of the dysregulation. While downregulation of RAS/ERK can lead to a thicker cortex from increased proliferation and an increased neuronal count [86], loss of Erk2 can induce such strong G1/S dysregulation that mice cells miss the time window of neurogenesis (E14.5–E16.5), resulting in fewer neurons, precocious astrogenesis, and potentially microcephaly [95]. The other key factor that controls neuron numbers is the balance between cell cycle re-entry (proliferative divisions) and exit (neurogenesis). During brain development, RGCs can divide symmetrically or asymmetrically. While symmetric divisions result in two daughter RGCs, asymmetric divisions produce a RGC and one another cell [96]. The newly generated cell can differentiate into a neuron, or become an IPC [97]. IPCs can undergo 1–3 proliferation cycles before differentiation to neurons [97, 98]. Cortical surface area and thickness are controlled by the mechanisms involved in RGC and IPC proliferation and differentiation decisions [99, 100]. Interestingly, G1/S transition rates might be associated with these cell decisions as symmetric divisions can have shorter G1/S transition times than asymmetric divisions [93, 101]. Evidence suggests that PI3K/AKT, RAS/ERK, WNT and β-catenin pathways are major players of these cell decisions as well. RGCs in a mouse model of Gsk3 knockout, a major convergence point of the signaling pathways (Fig. 6), show more highly active β-catenin and Notch pathways [102]. As a result, RGCs were locked in proliferative state with attenuated neurogenesis [102]. This resulted in expanded RGC pools, fewer IPCs, reduced cortical thickness and increased ventricular apical surface length [102]. Hence, it is tempting to speculate that perturbation of these four pathways in ASD could involve dysregulation of balance between proliferation and neurogenesis as well as neurogenesis and gliogenesis.

Disruption of cell fate and migration

Studies on MECP2, KAT2B, REELIN and FOXG1 hcASD genes suggest that they are associated with changes to the cell fate determination and neural migration processes in ASD through PI3K/AKT, RAS/ERK, WNT and β-catenin pathways (Table 1). Upregulation of WNT and β-catenin signaling, for example, prevents the multipolar to bipolar transition of pyramidal precursors [103]. Thus, neurons fail to migrate to the cortical plate and accumulate within the intermediate zone [88, 104]. Somatic mutations can also lead to dysregulation of these signaling pathways during brain development. Somatic activating mutations in the PI3K/AKT pathway are associated with hemimegalencephaly and focal cortical dysplasia syndromes that are marked by cortical dyslamination, dysmorphic neurons and loss of radial neuronal orientation [50, 105, 106]. Thus, in addition to modulating neuron development, the perturbed pathways in ASD also alter cell fate determination and neural migration.

Dysregulation of neurite outgrowth and neuronal function

The hcASD genes SHANK3, FMR1, CTNND2, CHD8, SYNGAP1, MECP2, PTEN, ARID1B and NF1 are associated with dysregulation of neurite outgrowth and neuronal function through the PI3K/AKT, RAS/ERK, WNT and β-catenin signaling pathways (Table 1). These pathways control soma size, dendritic arborization, axon generation, spine development and synapse function [184,185,186,187,188]. Activity of receptor tyrosine kinases, metabotropic glutamic receptors and NMDA receptors lead to the activation of PI3K/AKT and RAS/ERK signaling pathways [185, 189], and thereby influence synaptic plasticity by mediating expression and trafficking of AMPA receptors in excitatory synapses and controlling long-term depression (LTD) and long-term potentiation (LTP) responses [188,189,190]. PI3K/AKT and RAS/ERK signaling pathways also control processes associated with neural excitotoxicity and cell survival [191]. Interestingly, it seems that hcASD genes do not impact these pathways in the same way. For example, while mutations in Fmr1 and Pten lead to the over-activity of PI3K/AKT pathway with increased synaptogenesis and hyperconnectivity of the neurons [107,108,109], mutations in Mecp2 and Shank3 are reported to suppress the pathway, leading to delayed and sparse spine development and reduced synaptic amplitude [110, 111]. Interestingly, in cases of Mecp2 and Shank3, neurons could be partially rescued by activating PI3K/AKT pathway through Pten inhibition or IGF1 treatment, while downregulation of the pathway in Fmr1 null mice ameliorated aberrations in protein synthesis, dendritic spine density and cortical network connectivity [108, 109].

Finally, by prenatal injection of a small molecule that stabilizes axin, a component of the WNT and β-catenin signaling pathway, cell cycle proliferation is prolonged and causes an excess of layer 2 and 3 neurons and early brain overgrowth, abnormal synaptogenesis and increased excitatory neural activity [112]. This was accompanied by ASD-like abnormal social, vocalization, and ritualistic behaviors. These results strengthen the causal link between cell cycle disruption and ASD and also suggest that non-genetic etiologies may underlie deviant neurodevelopmental trajectories.

Thus, RAS/ERK, PI3K/AKT, WNT and β-catenin are highly integrated and pleiotropic, exhibiting different and successive roles throughout prenatal and early post-natal life (Fig. 6). Across ASD individuals, variation in how and when these pleiotropic pathways are dysregulated will cause early heterogeneity of pathophysiology and potentially later neural and clinical heterogeneous outcomes.

The prenatal maternal immune activation model of ASD

Non-genetic etiologies may account for 30–41% of the risk for ASD [113], and such factors may act independently or in combination with genetic factors [113]. A well-established non-genetic model system for studying ASD pathophysiology is the prenatal maternal immune activation (MIA) model [114,115,116]. The link between MIA and enhanced risk for ASD is bolstered by large-scale population-based studies showing small but significantly increased risk due to maternal prenatal infections [117,118,119,120,121,122]. MIA models have ASD-like social, vocalization, ritualistic, exploration and other behavioral deficits [123,124,125]. Current MIA ASD models expose developing rodent pups to bacterial or viral mimetics [126] to elicit strong immune responses. This is timed to roughly mimic infection between 8 to 12 weeks during the 1st trimester in humans, when neural progenitor cells are proliferating to expand cortical surface area and promote cortical layering [37, 39].

MIA strongly upregulates cell cycle gene expression and cell proliferation, and may cause brain overgrowth [127,128,129]. Similar to some ASD cases, MIA induces overproduction of neurons [129], and increases cortical thickness [129, 130] and brain size [130] as seen in many toddlers with ASD [5, 8, 10, 13, 14, 18]. Gene expression alterations also involve neuronal migration processes [128] that could underlie observed cortical layering defects, characterized by a 24% increase in neuron numbers in cortical layers II/III [131]. MIA can also induce more complex cortical phenotypes such as focal cortical dysplasia [81, 132], similar to those found in ASD [34] (Fig. 7). Also, cytoarchitecture heterogeneity is seen that is characteristic of ASD cases [34, 132]. When focal cortical dysplasia is present, ASD-like behaviors occur; but when its development is prevented, ASD-like behaviors do not occur [81].

Fig. 7

In a single litter, a single prenatal poly(I:C) injection may cause different cortical layering defects across pups that resemble some types of focal cortical dysplasias seen in different individuals with ASD.  a Expression of multiple layer-specific markers (II–IV and V, VI) in mouse cortex from Choi and colleagues [81, 132]. Typical mouse cortex layer development is shown in upper left corner (PBS), while heterogeneous types of focal cortical dysplasia are caused by prenatal maternal immune activation (MIA) by synthetic dsRNA, poly(I:C) as shown in the other three panels. b In a single litter, a single prenatal poly(I:C) injection may cause different layering defects across pups including protrusions, intrusions and laminar disorganization and other types of focal cortical dysplasia as well as pups with typical cortex. The cortical and ASD-like behavioral MIA-caused phenotypes are dependent on maternal IL-17a. c A 9 year old ASD postmortem case with ADNP gene mutation has focal macroscopic frontal cortical surface malformation (white arrow) and interruption of underlying cortical layering as visualized by expression of multiple layer-specific and cell type specific markers (see region marked by the two light blue arrows; see Fig. 1 in Stoner et al [34]). Different marker genes represented by different colors. This focal region also has clusters of mis-migrated cells (not shown in this section). Inset shows the same cortex location visualized by nissl staining to further reveal surface undulation and protrusion (see black arrow). A 2 year old ASD postmortem case shown in d with surface intrusions visualized by nissl staining and in e with surface intrusion visualized by multiple layer-specific and cell type specific markers [34]. Adapted from Choi et al. [132] and Stoner et al. [34]

In addition to causing dysregulation of proliferation, abnormal neuronal migration and dysplasia, increased brain size and ASD-like behavior, MIA animal models also lead to many other neuroanatomical and molecular abnormalities found in ASD (Table 2).

Table 2 ASD-like molecular, cellular, anatomical and behavioral abnormalities in MIA models

Given the diverse ASD-associated phenotypes that arise with a prenatal immune challenge, MIA-induced effects on neurodevelopment provide insights into the molecular mechanisms behind ASD and related neurodevelopmental disorders. Within the ASD neuropathological and molecular heterogeneous landscape, MIA disrupts fetal development by involving transcriptional programs that are abnormal in adult ASD brain tissue and genes with high-confidence ASD mutations or their downstream targets [127]. This evidence suggests shared disrupted pathways between genetic and non-genetic etiologies and the possibility for a much more relevant interplay between a genetic background at-risk for ASD and environmental triggers. Work by Le Belle et al. [130] identified that brain enlargement due to Pten haploinsufficiency in mouse increased from 8 to 44% when combined with MIA, thus demonstrating the interactive effects of MIA and ASD gene mutations in the disruption of cortical development. Such augmented disruption occurs via the activation of the cellular redox signaling in response to infection [130,133]. Reactive oxygen species (ROS) can increase stem cell self-renewal and neurogenesis through the reversible inactivation of PTEN and hyper-activation of the NADPH oxidase (NOX)-PI3K pathway [134], which ultimately, during early post-natal development, will result in enlarged brains and autistic behaviors.

MIA also causes long-lasting deleterious effects on the post-natal brain similar to those expected from germline mutations in patients with neurodevelopmental disorders [127]. Such effects likely involve the epigenetic dysregulation of transcriptional programs that are sensitive to environmental changes or insults [135,136,137]. Inflammatory mediators (e.g., cytokines) induce such alterations during neurodevelopment [138] by histone modifications [139], methylation changes at the promoter of ASD-critical genes (e.g., MECP2) [140] or genes involved in synaptic functions [141] and global methylation changes [136]. Importantly, increased levels of IL-6 alone recapitulate aspects of ASD pathophysiology [138, 142, 143]. At the molecular level, IL-6 increases the activity of DNA methyltransferases 1 (DNMT1) with activating effects on the JAK/STAT3, NF-κB and PI3K/AKT/mTOR signaling pathways [144,145,146,147,148] affecting the regulation of autophagy-related functions, that are required to maintain cellular homeostasis under stress [149], such as a prenatal insult. This provides a strong link between pro-inflammatory immune factors, body growth through activation of the mTOR pathway and uncontrolled proliferation typical of cancer-related disease [150, 151,152,153]. Genetic or epigenetic dysregulation of such pathways is associated with several neurodevelopmental disorders, in particular psychiatric, characterized by abnormal brain size (enlarged and reduced) [154, 155]. Consistently, we found that MIA alters key components of the TSC/mTOR signaling pathway with ultimate activation of the translation initiation factor EIF4E which is predicted to alter the regulation of neural progenitor cell divisions during midgestation [127, 156,157,158]. Such regulation may also be altered by activation of microglia cells under stress conditions including MIA and/or in response to increase levels of IL-6 [142]. Impairment in the regulation of microglia functions is consistently seen in ASD studies [42, 159, 160] and is likely involved in abnormal regulation of neuron numbers both at pre- and post-natal stages.

Accumulating evidence consolidates the idea that environmental models of ASD-associated phenotypes may provide valuable insights to help develop potential treatment, prevention, or intervention strategies. For example, MIA alters expression in pathways shared with those in fragile X syndrome for which advances in drug development are in progress. With a better understanding of mechanisms behind environmental etiologies of ASD, such as MIA, we could potentially identify therapeutic targets amenable to prevention and/or treatment later in life [161, 162]. In this scenario, drugs that successfully target those pathways in fragile X syndrome could potentially be re-purposed [127]. Other studies have used mesenchymal stem cells [163] or pharmacological treatment to block or antagonize the effect of MIA on purinergic [164] or inflammatory pathways [142, 165, 166].

Future directions: ASD Living Biology

Evidence shows that ASD begins during prenatal life, which is the least studied and understood of all developmental periods of ASD. This glaring gap poses a major barrier to progress in ASD research and treatment and  exists because nearly all current approaches—postmortem, molecular, genomic, genetic, computational and animal models—cannot get answers to foundational questions such as: What are the underlying molecular and cellular processes during fetal and early post-natal stages that cause ASD in each child, and how does this vary across children? How do different prenatal trajectories explain and predict heterogeneity in post-natal brain growth and functioning, behavior and clinical profiles in ASD toddlers? Are there subtypes that display normal fetal-stage development but begin abnormal development at post-natal stages?

Nor can current approaches effectively examine more targeted questions such as: How do different hcASD genes affect fetal processes, and how are those effects related to post-natal cognitive, language and social development? Is there a difference in the brain development trajectory between idiopathic ASD cases and ASD with mutations in hcASD risk genes? Since macrocephaly is more strongly related to ASD than to intellectual disability (ID) [62] and many hcASD genes such as CHD8 and WDFY3 cause dysregulation of proliferation and brain overgrowth [193, 177, 183], what other fetal mechanisms are altered by excess proliferation that lead to an ASD outcome? What are the fetal-stage processes that alter imbalance between excitation and inhibition that is proposed to explain learning, memory, sensorimotor, and cognitive deficits in ASD [167]?

Post-natal phenotype data alone cannot reveal fetal-stage biology, and fetal-stage cellular models alone cannot explain post-natal development and clinical heterogeneity. There is a need to bridge the gap between fetal and post-natal biology for living ASD toddlers, and this requires a paradigm shift. This paradigm we describe here, ASD Living Biology, approaches the fundamental questions above, by acquiring fetal and early post-natal measures using iPS cells derived from skin or blood at any age, and integrating them using a within-subjects design. Discovery of the subtypes of prenatal pathogenic processes and their interplay with post-natal experiences should be a major direction for ASD research.

The ASD Living Biology approach will enable the construction of quantitative multiscale models that could address the perturbations in fetal-to-post-natal development. These explanatory and predictive models of ASD could address the disorder at the individual, subtype and group level, when compared to models from typically developing children. ASD Living Biology models would link in vitro and in vivo data. In vitro data would include molecular, cellular and physiological measures of a child’s iPS cells, including measures of fetal-stage proliferation/differentiation, cell fate and growth, synaptogenesis, synaptic function and synchronized neural network activity. This iPSC based approach could then be connected with in vivo measurements from the same child, including their neural structural and functional, genetic and genomic, behavioral, psychometric, diagnostic and clinical outcome data. By thus integrating such within-child fetal and post-natal measures, and integrating these data, it will be possible to better understand prenatal molecular mechanisms leading to the development of ASD.

Interactions of post-natal biology and experiences with preceding prenatal biology

Future research could also determine whether some ASD prenatal trajectories are more deterministic of outcome phenotype, while others might be easily modified by experience, learning and interventions. The pleiotropic effect of many hcASD genes raises the testable hypothesis of a layered prenatal to post-natal path toward ASD in which the disorder may be dynamically impacted by post-natal changing functional roles of some ASD genes. It is also possible that heterogeneity in ASD outcomes may derive from the interplay of diverse prenatal dysregulations with post-natal exposures. Post-natal changes are thought to be reflected in changing behavioral and neurodevelopmental features [168] and some underlying mechanisms have been proposed [169]. Perhaps different prenatal pathogenic subtypes act as different general starting points from which diverse post-natal experiences lead to further variation in atypical development, some to higher and others to lower risk for ASD. For each child, prenatal starting points must be “worked around” to find optimal adaptations for that individual. As a result, more or less severe atypical behavior and cognitive outcomes may occur [170, 171]. ASD Living Biology studies could be designed to look at the interaction between atypical prenatal biology and post-natal experience-based adaptation and how this could lead to a spiral in early development that canalizes [172] over time toward multiple, heterogeneous end points (e.g., multifinality) [173]. Because neural circuits are sculpted by experience, future designs could examine whether atypical reduced social visual engagements from very early in life in ASD [174,175,176], are the product of some atypical prenatal to post-natal neural pathophysiology that causes an individual to engage in behavioral and cognitive adaptations that result in decreased sampling of the important social information necessary for typical social brain development. The more atypical such post-natal experience becomes, the more an individual’s development could become canalized for atypical outcomes.


Multiple lines of postmortem, cellular, molecular, genomic, genetic and animal model studies show that altered development in ASD can begin as early as the 1st and 2nd trimesters. Ninety-four percent of hcASD genes have peak expression prenatally, with the vast majority affecting proliferation/differentiation, cell fate, migration, neurite outgrowth and synaptogenesis. The majority are also pleiotropic, affecting multiple developmental stages, not just one. A commonly implicated pathway, RAS/ERK-PI3K/AKT, is also pleiotropic and impacts multiple prenatal stages from proliferation to synapse formation and function. In different ASD individuals, variation in how and when these pleiotropic pathways are dysregulated will lead to different, even opposing effects, producing prenatal as well as later neural and clinical heterogeneity. Thus, an excess or reduction of synapse formation may occur in different ASD cases; excess brain growth occurs in most while reduced size occurs in a small subset. Nonetheless, in each individual ASD child, multiple fetal-stage processes are disrupted; one pathogenesis pattern is illustrated in Fig. 8 and is based on Marchetto et al. [54]. Thus, the pathogenesis of ASD is not set at one point in time and does not reside in one process, but rather is a cascade of pathogenic processes. This cascade can begin as early as the first trimester, with alterations in cell proliferation and differentiation. The process then continues throughout prenatal life and into the early post-natal period of life. Affected regions include frontal, temporal, parietal, occipital, cerebellar, striatal, amygdala and hippocampal regions (Fig. 4). Remarkably, one ASD child-based cellular model finds a 10-fold decrease in spontaneous neural activity and a 6-fold decrease in synchronized bursts of neural network activity, a type of defect theorized long ago [6]. This dysfunctional network endpoint is not the “cause” of ASD but rather appears to stand at the end of a long chain of prenatal and early post-natal pathogenic changes (Fig. 8).

Fig. 8

ASD is a multistage, progressive disorder of prenatal brain development. ASD children show a continuum of disorder severity because a wide range of heterogeneous insults can affect brain development in a not fully deterministic way. We propose the general theory that ASD arises from disruption of gene regulatory circuits with multiscale, hierarchical consequences on brain development starting from very early fetal stages. One possible prenatal trajectory of ASD is illustrated here. As compared with four fetal stages illustrated in typical development (lower panel; increasing fetal age from left to right), this ASD trajectory begins in the 1st and 2nd trimesters with abnormally high rates of proliferation; this results in excess neural precursor cells (ASD first panel). Disorder continues with disruption of migration, laminar disorganization, reduced cell growth, and reduced neurite outgrowth, resulting in neurons with a 10-fold decrease in spontaneous neural activity (ASD second panel). At still later stages, ASD neurons show defects in synaptogenesis, receptor and neurotransmitter development (ASD third panel). This deviant development of neurons leads to abnormal neural circuitry with a 6-fold decrease in synchronized bursts of neural network activity (ASD fourth panel). This also illustrates that ASD pathogenesis is not set at one point in time and does not reside in one process, but rather is a cascade of pathogenic processes. Different causes and prenatal times of insult combined with individual-dependent background genetics may alter details of developmental trajectories, resulting in differences in number, size and type of neurons in different cortical layers as well as number and functionality of synapses. This fetal heterogeneity leads to post-natal heterogeneity in neural circuits, behavior and clinical outcomes. Discovery of prenatal causes, processes and trajectories as they occur in children with ASD requires a paradigm shift: the ASD Living Biology approach. Courtesy of Eric Courchesne and Vahid H. Gazestani

ASD is a multi-etiology, multi-stage, progressive disorder that spans most of fetal life. In our theory, a single perturbation can trigger a cascade of pathogenic changes, such as an MIA event, a single fetal injection of XAV939 [112] or PTEN mutation in a child [54]. Multiple perturbations may substantially amplify both the severity of disorder and outcome heterogeneity, such as, for example, a combination of PTEN mutation and MIA [130]. Moreover, many known and proposed ASD etiologies (e.g., MECP2, PTEN, MIA, XAV939) may perturb the pleiotropic RAS/ERK-PI3K/AKT pathway (Fig. 6), which in turn modulates each of the ASD-critical fetal and early post-natal stages discussed here. Dysregulated proliferation/differentiation can be a potent perturbation because it can lead to abnormal changes in subsequent stages of cell fate, migration, organization, maturation, and synapse and neural development [54, 112]. Cell and animal models of high-confidence ASD genes, such as CHD8, PTEN, WDFY3, definitively show disruption of cell proliferation (Fig. 5; Table S2); Fang et al. show robust synaptic, neural and behavioral downstream effects of excess neuron proliferation [112], and ASD patient-derived iPSC models show that excess proliferation is a robust early fetal stage defect in every case examined [54, 55].

Culprit prenatal perturbations do not necessarily produce identical neural and clinical outcomes even when the perturbations are themselves identical in siblings. The Choi and colleagues [132, 81] MIA ASD mouse model study showed that the same fetal MIA perturbation of littermates causes patches of focal cortical dysplasia that have marked heterogeneity, analogous to heterogeneity found in cortex in unrelated individual ASD cases postmortem [34] (Fig. 7). The Wdfy3 mutation mouse model of ASD likewise displays heterogeneity of migration and focal patch defects across individual animals, as well as disrupted proliferation/differentiation and cortical overgrowth [177]. In Courchesne et al. [24], two ASD individuals had >100% the normal mean prefrontal neuron number, but one had small neurons and a modestly enlarged brain weight while the other had typical neuron size and one of the largest brain weights ever recorded for ASD. In the Marchetto et al. [54] study, even though neural progenitors from every ASD toddler doubled cell numbers faster than every control, the proliferation rates among ASD toddlers varied and that variation correlated with variation in MRI volume.

Because ASD begins in prenatal and early post-natal life, there is an ethical demand for early detection, intervention and services. When it is not detected in an infant or toddler, it is because it was missed [178]. Studies demonstrate that ASD risk can be measured as young as 12 to 24 months using parent report screening tools such as the CSBS IT-Checklist and M-CHAT at well-baby check-ups with follow-up confirmation at ASD specialty clinics [179, 180]. This screening procedure is fast, easy, inexpensive and effective, and can be done in any pediatric office or clinic [179]. Studies show that when pediatricians and ASD specialty clinics work together, risk detection and diagnostic evaluation can occur as early as 12 to 20 months, and interventions soon thereafter [179, 181].

Early interventions and services may improve an ASD child’s developmental outcome and help parents at a crucial time in human brain development. During the first post-natal years, the human brain undergoes a profound period of establishing and refining neural connections, and this is the basis for the emergence of higher-order social, language and cognitive networks and behavior. This important developmental step of the construction of functional and adaptive neural circuits is dependent on adaptive neural responses to input from the environment. If an infant or toddler with ASD is identified and behavioral treatment begun before or while early brain connections are being actively established, then brain function for that toddler stands the best chance of being improved. This is superior to treatment that begins late and after abnormal mature circuitry is already established. It is for this very reason that the early identification and treatment of ASD is essential and ethically demanded [181].

Lastly, to address the progressive prenatal beginnings and likely prenatal to post-natal experience-dependent interactions in ASD, new treatment designs are needed. We advocate coordinated in vitro and in vivo within-subject ASD Living Biology research designs to provide early-age molecular, cellular, and neuronal functional developmental explanations for individual differences as well as across ASD commonalities. Advances in stem cell model systems enable this [182]: Patient-derived brain organoids allow investigation of fetal processes that are remarkably similar to in vivo development. Within-child in vitro and in vivo designs could reveal prenatal and early post-natal bases of outcome clinical heterogeneity. Through this ASD Living Biology approach, relationships between prenatal development and post-natal experience, learning, brain growth and function, clinical presentation and progression, and treatment responsiveness may be defined at the individual level, thus enabling the development of precision medicine approaches with truly beneficial interventions.


  1. 1.

    Kanner L. Autistic disturbances of affective contact. Nerv Child. 1943;2:217–50.

    Google Scholar 

  2. 2.

    Constantino JN, Marrus N. The early origins of autism. Child Adolesc Psychiatr Clin N Am. 2017;26:555–70.

    PubMed  Google Scholar 

  3. 3.

    Dawson G, Meltzoff AN, Osterling J, Rinaldi J, Brown E. Children with autism fail to orient to naturally occurring social stimuli. J Autism Dev Disord. 1998;28:479–85.

    CAS  PubMed  Google Scholar 

  4. 4.

    Lord C, Bishop S, Anderson D. Developmental trajectories as autism phenotypes. Am J Med Genet C Semin Med Genet. 2015;169:198–208.

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    Courchesne E, Karns C, Davis HR, Ziccardi R, Carper R, Tigue Z, et al. Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study. Neurology. 2001;57:245–54.

    CAS  PubMed  Google Scholar 

  6. 6.

    Courchesne E, Pierce K. Why the frontal cortex in autism might be talking only to itself: local over-connectivity but long-distance disconnection. Curr Opin Neurobiol. 2005;15:225–30.

    CAS  PubMed  Google Scholar 

  7. 7.

    Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, et al. Mapping early brain development in autism. Neuron. 2007;56:399–413.

    CAS  PubMed  Google Scholar 

  8. 8.

    Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effects. Neuroimage. 2002;16:1038–51.

    PubMed  Google Scholar 

  9. 9.

    Carper RA, Courchesne E. Localized enlargement of the frontal cortex in early autism. Biol Psychiatry. 2005;57:126–33.

    PubMed  Google Scholar 

  10. 10.

    Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA, et al. Brain structural abnormalities in young children with autism spectrum disorder. Neurology. 2002;59:184–92.

    CAS  PubMed  Google Scholar 

  11. 11.

    Hazlett HC, Poe M, Gerig G, Smith RG, Provenzale J, Ross A, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry. 2005;62:1366–76.

    PubMed  Google Scholar 

  12. 12.

    Stanfield AC, McIntosh AM, Spencer MD, Philip R, Gaur S, Lawrie SM. Towards a neuroanatomy of autism: a systematic review and meta-analysis of structural magnetic resonance imaging studies. Eur Psychiatry. 2008;23:289–99.

    PubMed  Google Scholar 

  13. 13.

    Shen MD, Nordahl CW, Young GS, Wootton-Gorges SL, Lee A, Liston SE, et al. Early brain enlargement and elevated extra-axial fluid in infants who develop autism spectrum disorder. Brain. 2013;136(Pt 9):2825–35.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Schumann CM, Bloss CS, Barnes CC, Wideman GM, Carper RA, Akshoomoff N, et al. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. J Neurosci. 2010;30:4419–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Zielinski BA, Prigge MB, Nielsen JA, Froehlich AL, Abildskov TJ, Anderson JS, et al. Longitudinal changes in cortical thickness in autism and typical development. Brain. 2014;137(Pt 6):1799–812.

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Lange N, Travers BG, Bigler ED, Prigge MB, Froehlich AL, Nielsen JA, et al. Longitudinal volumetric brain changes in autism spectrum disorder ages 6-35 years. Autism Res. 2015;8:82–93.

    PubMed  Google Scholar 

  17. 17.

    Ohta H, Nordahl CW, Iosif AM, Lee A, Rogers S, Amaral DG. Increased surface area, but not cortical thickness, in a subset of young boys with autism spectrum disorder. Autism Res. 2016;9:232–48.

    PubMed  Google Scholar 

  18. 18.

    Hazlett HC, Gu H, Munsell BC, Kim SH, Styner M, Wolff JJ, et al. Early brain development in infants at high risk for autism spectrum disorder. Nature. 2017;542:348–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Solso S, Xu R, Proudfoot J, Hagler DJ Jr., Campbell K, Venkatraman V, et al. Diffusion tensor imaging provides evidence of possible axonal overconnectivity in frontal lobes in autism spectrum disorder toddlers. Biol Psychiatry. 2016;79:676–84.

    PubMed  Google Scholar 

  20. 20.

    Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003;290:337–44.

    PubMed  Google Scholar 

  21. 21.

    Dementieva YA, Vance DD, Donnelly SL, Elston LA, Wolpert CM, Ravan SA, et al. Accelerated head growth in early development of individuals with autism. Pediatr Neurol. 2005;32:102–8.

    PubMed  Google Scholar 

  22. 22.

    Dawson G, Munson J, Webb SJ, Nalty T, Abbott R, Toth K. Rate of head growth decelerates and symptoms worsen in the second year of life in autism. Biol Psychiatry. 2007;61:458–64.

    PubMed  Google Scholar 

  23. 23.

    Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. 2005;58:1–9.

    PubMed  Google Scholar 

  24. 24.

    Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA. 2011;306:2001–10.

    CAS  PubMed  Google Scholar 

  25. 25.

    Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci. 2005;23:183–7.

    PubMed  Google Scholar 

  26. 26.

    Levy J, Coussement A, Dupont C, Guimiot F, Baumann C, Viot G, et al. Molecular and clinical delineation of 2p15p16.1 microdeletion syndrome. Am J Med Genet A. 2017;173:2081–7.

    CAS  PubMed  Google Scholar 

  27. 27.

    Bernier R, Steinman KJ, Reilly B, Wallace AS, Sherr EH, Pojman N, et al. Clinical phenotype of the recurrent 1q21.1 copy-number variant. Genet Med. 2016;18:341–9.

    PubMed  Google Scholar 

  28. 28.

    Jang DH, Chae H, Kim M. Autistic and Rett-like features associated with 2q33.3-q34 interstitial deletion. Am J Med Genet A. 2015;167A:2213–8.

    PubMed  Google Scholar 

  29. 29.

    Kumar RA, Sudi J, Babatz TD, Brune CW, Oswald D, Yen M, et al. A de novo 1p34.2 microdeletion identifies the synaptic vesicle gene RIMS3 as a novel candidate for autism. J Med Genet. 2010;47:81–90.

    CAS  PubMed  Google Scholar 

  30. 30.

    Sacco R, Gabriele S, Persico AM. Head circumference and brain size in autism spectrum disorder: a systematic review and meta-analysis. Psychiatry Res. 2015;234:239–51.

    PubMed  Google Scholar 

  31. 31.

    Donovan AP, Basson MA. The neuroanatomy of autism—a developmental perspective. J Anat. 2017;230:4–15.

    PubMed  Google Scholar 

  32. 32.

    Packer A. Neocortical neurogenesis and the etiology of autism spectrum disorder. Neurosci Biobehav Rev. 2016;64:185–95.

    PubMed  Google Scholar 

  33. 33.

    Kaushik G, Zarbalis KS. Prenatal neurogenesis in autism spectrum disorders. Front Chem. 2016;4:12.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, et al. Patches of disorganization in the neocortex of children with autism. N Engl J Med. 2014;370:1209–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Gotz M, Huttner WB. The cell biology of neurogenesis. Nat Rev Mol Cell Biol. 2005;6:777–88.

    PubMed  Google Scholar 

  36. 36.

    Bayatti N, Moss JA, Sun L, Ambrose P, Ward JF, Lindsay S, et al. A molecular neuroanatomical study of the developing human neocortex from 8 to 17 postconceptional weeks revealing the early differentiation of the subplate and subventricular zone. Cereb Cortex. 2008;18:1536–48.

    PubMed  Google Scholar 

  37. 37.

    Hansen DV, Lui JH, Parker PR, Kriegstein AR. Neurogenic radial glia in the outer subventricular zone of human neocortex. Nature. 2010;464:554–61.

    CAS  PubMed  Google Scholar 

  38. 38.

    Fish JL, Dehay C, Kennedy H, Huttner WB. Making bigger brains-the evolution of neural-progenitor-cell division. J Cell Sci. 2008;121(Pt 17):2783–93.

    CAS  PubMed  Google Scholar 

  39. 39.

    Kriegstein A, Noctor S, Martinez-Cerdeno V. Patterns of neural stem and progenitor cell division may underlie evolutionary cortical expansion. Nat Rev Neurosci. 2006;7:883–90.

    CAS  PubMed  Google Scholar 

  40. 40.

    van Kooten IA, Palmen SJ, von Cappeln P, Steinbusch HW, Korr H, Heinsen H, et al. Neurons in the fusiform gyrus are fewer and smaller in autism. Brain. 2008;131(Pt 4):987–99.

    PubMed  Google Scholar 

  41. 41.

    Santos M, Uppal N, Butti C, Wicinski B, Schmeidler J, Giannakopoulos P, et al. Von Economo neurons in autism: a stereologic study of the frontoinsular cortex in children. Brain Res. 2011;1380:206–17.

    CAS  PubMed  Google Scholar 

  42. 42.

    Chow ML, Pramparo T, Winn ME, Barnes CC, Li HR, Weiss L, et al. Age-dependent brain gene expression and copy number anomalies in autism suggest distinct pathological processes at young versus mature ages. PLoS Genet. 2012;8:e1002592.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Rabinowicz T, de Courten-Myers GM, Petetot JM, Xi G, de los Reyes E. Human cortex development: estimates of neuronal numbers indicate major loss late during gestation. J Neuropathol Exp Neurol. 1996;55:320–8.

    CAS  PubMed  Google Scholar 

  44. 44.

    Gohlke JM, Griffith WC, Faustman EM. Computational models of neocortical neuronogenesis and programmed cell death in the developing mouse, monkey, and human. Cereb Cortex. 2007;17:2433–42.

    PubMed  Google Scholar 

  45. 45.

    Wegiel J, Kuchna I, Nowicki K, Imaki H, Marchi E, Ma SY, et al. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol. 2010;119:755–70.

    PubMed  PubMed Central  Google Scholar 

  46. 46.

    Varghese M, Keshav N, Jacot-Descombes S, Warda T, Wicinski B, Dickstein DL, et al. Autism spectrum disorder: neuropathology and animal models. Acta Neuropathol. 2017;134:537–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Hutsler JJ, Casanova MF. Review: Cortical construction in autism spectrum disorder: columns, connectivity and the subplate. Neuropathol Appl Neurobiol. 2016;42:115–34.

    PubMed  Google Scholar 

  48. 48.

    Bailey A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, et al. A clinicopathological study of autism. Brain. 1998;121(Pt 5):889–905.

    PubMed  Google Scholar 

  49. 49.

    D’Gama AM, Pochareddy S, Li M, Jamuar SS, Reiff RE, Lam AN, et al. Targeted DNA sequencing from autism spectrum disorder brains implicates multiple genetic mechanisms. Neuron. 2015;88:910–7.

    PubMed  PubMed Central  Google Scholar 

  50. 50.

    McConnell MJ, Moran JV, Abyzov A, Akbarian S, Bae T, Cortes-Ciriano I et al. Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network. Science. 2017;356.

  51. 51.

    Avino TA, Hutsler JJ. Abnormal cell patterning at the cortical gray-white matter boundary in autism spectrum disorders. Brain Res. 2010;1360:138–46.

    CAS  PubMed  Google Scholar 

  52. 52.

    Raymond GV, Bauman ML, Kemper TL. Hippocampus in autism: a Golgi analysis. Acta Neuropathol. 1996;91:117–9.

    CAS  PubMed  Google Scholar 

  53. 53.

    Jacot-Descombes S, Uppal N, Wicinski B, Santos M, Schmeidler J, Giannakopoulos P, et al. Decreased pyramidal neuron size in Brodmann areas 44 and 45 in patients with autism. Acta Neuropathol. 2012;124:67–79.

    CAS  PubMed  Google Scholar 

  54. 54.

    Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria KC, et al. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol Psychiatry. 2016;22:820–35.

    PubMed  PubMed Central  Google Scholar 

  55. 55.

    Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, et al. FOXG1-dependent dysregulation of GABA/Glutamate neuron differentiation in autism spectrum disorders. Cell. 2015;162:375–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Pramparo T, Lombardo MV, Campbell K, Barnes CC, Marinero S, Solso S, et al. Cell cycle networks link gene expression dysregulation, mutation, and brain maldevelopment in autistic toddlers. Mol Syst Biol. 2015;11:841.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014;37:95–105.

    CAS  PubMed  Google Scholar 

  58. 58.

    O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485:246–50.

    PubMed  PubMed Central  Google Scholar 

  59. 59.

    De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–15.

    PubMed  PubMed Central  Google Scholar 

  60. 60.

    Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485:237–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Stessman HA, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M, et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat Genet. 2017;49:515–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, et al. Excess of rare, inherited truncating mutations in autism. Nat Genet. 2015;47:582–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    O’Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43:585–9.

    PubMed  PubMed Central  Google Scholar 

  66. 66.

    Kosmicki JA, Samocha KE, Howrigan DP, Sanders SJ, Slowikowski K, Lek M, et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet. 2017;49:504–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. 2013;155:997–1007.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V, et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell. 2013;155:1008–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468:263–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003;302:826–30.

    CAS  PubMed  Google Scholar 

  71. 71.

    Li H, Zhong X, Chau KF, Santistevan NJ, Guo W, Kong G, et al. Cell cycle-linked MeCP2 phosphorylation modulates adult neurogenesis involving the Notch signalling pathway. Nat Commun. 2014;5:5601.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist. 2004;10:118–28.

    CAS  PubMed  Google Scholar 

  73. 73.

    Mellios N, Feldman DA, Sheridan SD, Ip JPK, Kwok S, Amoah SK et al. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling. Mol Psychiatry 2017; 23:1051-65.

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Zhang ZN, Freitas BC, Qian H, Lux J, Acab A, Trujillo CA, et al. Layered hydrogels accelerate iPSC-derived neuronal maturation and reveal migration defects caused by MeCP2 dysfunction. Proc Natl Acad Sci USA. 2016;113:3185–90.

    CAS  PubMed  Google Scholar 

  75. 75.

    Larimore JL, Chapleau CA, Kudo S, Theibert A, Percy AK, Pozzo-Miller L. Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobiol Dis. 2009;34:199–211.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18:147–57.

    CAS  PubMed  Google Scholar 

  77. 77.

    Zhao H, Tu Z, Xu H, Yan S, Yan H, Zheng Y, et al. Altered neurogenesis and disrupted expression of synaptic proteins in prefrontal cortex of SHANK3-deficient non-human primate. Cell Res. 2017;27:1293–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Krishnan A, Zhang R, Yao V, Theesfeld CL, Wong AK, Tadych A, et al. Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nat Neurosci. 2016;19:1454–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 2014;94:677–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. 80.

    Sahin M, Sur M Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science. 2015; 350.

  81. 81.

    Yim YS, Park A, Berrios J, Lafourcade M, Pascual LM, Soares N, et al. Reversing behavioural abnormalities in mice exposed to maternal inflammation. Nature. 2017;549:482–7.

    PubMed  Google Scholar 

  82. 82.

    Wen Y, Alshikho MJ, Herbert MR. Pathway Network Analyses for Autism Reveal Multisystem Involvement, Major Overlaps with Other Diseases and Convergence upon MAPK and Calcium Signaling. PLoS ONE. 2016;11:e0153329.

    PubMed  PubMed Central  Google Scholar 

  83. 83.

    Luo W, Zhang C, Jiang YH, Brouwer CR. Systematic reconstruction of autism biology from massive genetic mutation profiles. Sci Adv 2018; 4(4): e1701799.

    PubMed  PubMed Central  Google Scholar 

  84. 84.

    Kalkman HO. A review of the evidence for the canonical Wnt pathway in autism spectrum disorders. Mol Autism. 2012;3:10.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85.

    Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40:139–146.

    CAS  PubMed  Google Scholar 

  86. 86.

    Rhim JH, Luo X, Gao D, Xu X, Zhou T, Li F, et al. Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells. Sci Rep. 2016;6:26547.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Chen Y, Huang WC, Sejourne J, Clipperton-Allen AE, Page DT. Pten mutations alter brain growth trajectory and allocation of cell types through elevated beta-catenin signaling. J Neurosci. 2015;35:10252–67.

    CAS  PubMed  Google Scholar 

  88. 88.

    Munji RN, Choe Y, Li G, Siegenthaler JA, Pleasure SJ. Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. J Neurosci. 2011;31:1676–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Zhang J, Shemezis JR, McQuinn ER, Wang J, Sverdlov M, Chenn A. AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development. Neural Dev. 2013;8:7.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. 90.

    Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, et al. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012;150:816–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Miller FD, Gauthier AS. Timing is everything: making neurons versus glia in the developing cortex. Neuron. 2007;54:357–69.

    CAS  PubMed  Google Scholar 

  92. 92.

    Caviness VS Jr., Takahashi T. Proliferative events in the cerebral ventricular zone. Brain Dev. 1995;17:159–63.

    PubMed  Google Scholar 

  93. 93.

    Dehay C, Kennedy H. Cell-cycle control and cortical development. Nat Rev Neurosci. 2007;8:438–50.

    CAS  PubMed  Google Scholar 

  94. 94.

    Subtil-Rodriguez A, Vazquez-Chavez E, Ceballos-Chavez M, Rodriguez-Paredes M, Martin-Subero JI, Esteller M, et al. The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res. 2014;42:2185–96.

    CAS  PubMed  Google Scholar 

  95. 95.

    Samuels IS, Karlo JC, Faruzzi AN, Pickering K, Herrup K, Sweatt JD, et al. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci. 2008;28:6983–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Chenn A, McConnell SK. Cleavage orientation and the asymmetric inheritance of Notch1 immunoreactivity in mammalian neurogenesis. Cell. 1995;82:631–41.

    CAS  PubMed  Google Scholar 

  97. 97.

    Noctor SC, Martinez-Cerdeno V, Ivic L, Kriegstein AR. Cortical neurons arise in symmetric and asymmetric division zones and migrate through specific phases. Nat Neurosci. 2004;7:136–44.

    CAS  PubMed  Google Scholar 

  98. 98.

    Wu SX, Goebbels S, Nakamura K, Nakamura K, Kometani K, Minato N, et al. Pyramidal neurons of upper cortical layers generated by NEX-positive progenitor cells in the subventricular zone. Proc Natl Acad Sci USA. 2005;102:17172–7.

    CAS  PubMed  Google Scholar 

  99. 99.

    Pontious A, Kowalczyk T, Englund C, Hevner RF. Role of intermediate progenitor cells in cerebral cortex development. Dev Neurosci. 2008;30:24–32.

    CAS  PubMed  Google Scholar 

  100. 100.

    Lui JH, Hansen DV, Kriegstein AR. Development and evolution of the human neocortex. Cell. 2011;146:18–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Calegari F, Haubensak W, Haffner C, Huttner WB. Selective lengthening of the cell cycle in the neurogenic subpopulation of neural progenitor cells during mouse brain development. J Neurosci. 2005;25:6533–8.

    CAS  PubMed  Google Scholar 

  102. 102.

    Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci. 2009;12:1390–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. 103.

    Boitard M, Bocchi R, Egervari K, Petrenko V, Viale B, Gremaud S, et al. Wnt signaling regulates multipolar-to-bipolar transition of migrating neurons in the cerebral cortex. Cell Rep. 2015;10:1349–61.

    CAS  PubMed  Google Scholar 

  104. 104.

    Morgan-Smith M, Wu Y, Zhu X, Pringle J, Snider WD. GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation. eLife. 2014;3:e02663.

    PubMed  PubMed Central  Google Scholar 

  105. 105.

    Jansen LA, Mirzaa GM, Ishak GE, O’Roak BJ, Hiatt JB, Roden WH, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain. 2015;138(Pt 6):1613–28.

    PubMed  PubMed Central  Google Scholar 

  106. 106.

    Casanova MF, El-Baz AS, Kamat SS, Dombroski BA, Khalifa F, Elnakib A, et al. Focal cortical dysplasias in autism spectrum disorders. Acta Neuropathol Commun. 2013;1:67.

    PubMed  PubMed Central  Google Scholar 

  107. 107.

    Huang WC, Chen Y, Page DT. Hyperconnectivity of prefrontal cortex to amygdala projections in a mouse model of macrocephaly/autism syndrome. Nat Commun. 2016;7:13421.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. 108.

    Gross C, Chang CW, Kelly SM, Bhattacharya A, McBride SM, Danielson SW, et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. Cell Rep. 2015;11:727–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Gross C, Raj N, Molinaro G, Allen AG, Whyte AJ, Gibson JR et al. Selective role of the catalytic PI3K subunit p110beta in impaired higher order cognition in fragile X syndrome. Cell Rep 2015;11:681–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. 110.

    Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009;106:2029–34.

    CAS  PubMed  Google Scholar 

  111. 111.

    Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism. 2010;1:15.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. 112.

    Fang WQ, Chen WW, Jiang L, Liu K, Yung WH, Fu AK, et al. Overproduction of upper-layer neurons in the neocortex leads to autism-like features in mice. Cell Rep. 2014;9:1635–43.

    CAS  PubMed  Google Scholar 

  113. 113.

    Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014;46:881–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. 114.

    Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17:389–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. 115.

    Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009;204:313–21.

    CAS  PubMed  Google Scholar 

  116. 116.

    Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology. 2017;42:284–98.

    CAS  PubMed  Google Scholar 

  117. 117.

    Atladottir HO, Thorsen P, Ostergaard L, Schendel DE, Lemcke S, Abdallah M, et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010;40:1423–30.

    PubMed  Google Scholar 

  118. 118.

    Atladottir HO, Thorsen P, Schendel DE, Ostergaard L, Lemcke S, Parner ET. Association of hospitalization for infection in childhood with diagnosis of autism spectrum disorders: a Danish cohort study. Arch Pediatr Adolesc Med. 2010;164:470–7.

    PubMed  Google Scholar 

  119. 119.

    Lee BK, Magnusson C, Gardner RM, Blomstrom A, Newschaffer CJ, Burstyn I, et al. Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. Brain Behav Immun. 2015;44:100–5.

    Google Scholar 

  120. 120.

    Jiang HY, Xu LL, Shao L, Xia RM, Yu ZH, Ling ZX, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: a systematic review and meta-analysis. Brain Behav Immun. 2016;58:165–72.

    PubMed  Google Scholar 

  121. 121.

    Hornig M, Bresnahan MA, Che X, Schultz AF, Ukaigwe JE, Eddy ML et al. Prenatal fever and autism risk. Mol Psychiatry. 2018;23:759–66.

    PubMed  PubMed Central  Google Scholar 

  122. 122.

    Brown AS, Sourander A, Hinkka-Yli-Salomaki S, McKeague IW, Sundvall J, Surcel HM. Elevated maternal C-reactive protein and autism in a national birth cohort. Mol Psychiatry. 2014;19:259–64.

    CAS  PubMed  Google Scholar 

  123. 123.

    Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci. 2003;23:297–302.

    Google Scholar 

  124. 124.

    Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun. 2012;26:607–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  125. 125.

    Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27:10695–702.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. 126.

    Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. Science. 2016;353:772–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. 127.

    Lombardo MV, Moon HM, Su J, Palmer TD, Courchesne E, Pramparo T. Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. Mol Psychiatry. 2017;23:1001–13.

    PubMed  PubMed Central  Google Scholar 

  128. 128.

    Oskvig DB, Elkahloun AG, Johnson KR, Phillips TM, Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav Immun. 2012;26:623–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. 129.

    Smith SE, Elliott RM, Anderson MP. Maternal immune activation increases neonatal mouse cortex thickness and cell density. J Neuroimmune Pharmacol. 2012;7:529–32.

    PubMed  PubMed Central  Google Scholar 

  130. 130.

    Le Belle JE, Sperry J, Ngo A, Ghochani Y, Laks DR, Lopez-Aranda M, et al. Maternal inflammation contributes to brain overgrowth and autism-associated behaviors through altered redox signaling in stem and progenitor cells. Stem Cell Rep. 2014;3:725–34.

    Google Scholar 

  131. 131.

    Soumiya H, Fukumitsu H, Furukawa S. Prenatal immune challenge compromises the normal course of neurogenesis during development of the mouse cerebral cortex. J Neurosci Res. 2011;89:1575–85.

    CAS  PubMed  Google Scholar 

  132. 132.

    Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351:933–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133.

    Lanté F, Meunier J, Guiramand J, Maurice T, Cavalier M, de Jesus Ferreira MC, et al. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radic Biol Med. 2006;42:1231–45.

    Google Scholar 

  134. 134.

    Le Belle JE, Orozco NM, Paucar AA, Saxe JP, Mottahedeh J, Pyle AD, et al. Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell. 2011;8:59–71.

    PubMed  PubMed Central  Google Scholar 

  135. 135.

    Coiro P, Padmashri R, Suresh A, Spartz E, Pendyala G, Chou S, et al. Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders. Brain Behav Immun. 2015;50:249–58.

    PubMed  PubMed Central  Google Scholar 

  136. 136.

    Richetto J, Massart R, Weber-Stadlbauer U, Szyf M, Riva MA, Meyer U. Genome-wide DNA Methylation Changes in a Mouse Model of Infection-Mediated Neurodevelopmental Disorders. Biol Psychiatry. 2017;81:265–76.

    CAS  PubMed  Google Scholar 

  137. 137.

    Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, Meyer U. Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. Mol Psychiatry. 2017;22:102–12.

    CAS  PubMed  Google Scholar 

  138. 138.

    Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;64:61–78.

    CAS  Google Scholar 

  139. 139.

    Tang B, Jia H, Kast RJ, Thomas EA. Epigenetic changes at gene promoters in response to immune activation in utero. Brain Behav Immun. 2013;30:168–75.

    CAS  PubMed  Google Scholar 

  140. 140.

    Basil P, Li Q, Dempster EL, Mill J, Sham PC, Wong CC, et al. Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain. Transl Psychiatry. 2014;4:e434.

    CAS  PubMed  PubMed Central  Google Scholar 

  141. 141.

    Labouesse MA, Dong E, Grayson DR, Guidotti A, Meyer U. Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex. Epigenetics. 2015;10:1143–55.

    PubMed  PubMed Central  Google Scholar 

  142. 142.

    Gumusoglu SB, Fine RS, Murray SJ, Bittle JL, Stevens HE. The role of IL-6 in neurodevelopment after prenatal stress. Brain Behav Immun. 2017;65:274–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  143. 143.

    Wu WL, Hsiao EY, Yan Z, Mazmanian SK, Patterson PH. The placental interleukin-6 signaling controls fetal brain development and behavior. Brain Behav Immun. 2017;62:11–23.

    CAS  PubMed  Google Scholar 

  144. 144.

    Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136:547–59.

    CAS  PubMed  Google Scholar 

  145. 145.

    Huang L, Hu B, Ni J, Wu J, Jiang W, Chen C, et al. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res. 2016;35:27.

    PubMed  PubMed Central  Google Scholar 

  146. 146.

    Gerard C, Gonze D, Lemaigre F, Novak B. A model for the epigenetic switch linking inflammation to cell transformation: deterministic and stochastic approaches. PLoS Comput Biol. 2014;10:e1003455.

    PubMed  PubMed Central  Google Scholar 

  147. 147.

    Hodge DR, Cho E, Copeland TD, Guszczynski T, Yang E, Seth AK, et al. IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. Cancer Genom Proteom. 2007;4:387–98.

    CAS  Google Scholar 

  148. 148.

    Mundi PS, Sachdev J, McCourt C, Kalinsky K. AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol. 2016;82:943–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  149. 149.

    You L, Wang Z, Li H, Shou J, Jing Z, Xie J, et al. The role of STAT3 in autophagy. Autophagy. 2015;11:729–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  150. 150.

    Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–18.

    PubMed  PubMed Central  Google Scholar 

  151. 151.

    Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6:3011–14.

    CAS  PubMed  Google Scholar 

  152. 152.

    Fleming JD, Giresi PG, Lindahl-Allen M, Krall EB, Lieb JD, Struhl K. STAT3 acts through pre-existing nucleosome-depleted regions bound by FOS during an epigenetic switch linking inflammation to cancer. Epigenetics Chromatin. 2015;8:7.

    CAS  PubMed  PubMed Central  Google Scholar 

  153. 153.

    Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 2016;138:2570–8.

    CAS  PubMed  Google Scholar 

  154. 154.

    Wang L, Zhou K, Fu Z, Yu D, Huang H, Zang X, et al. Brain Development and Akt Signaling: the Crossroads of Signaling Pathway and Neurodevelopmental Diseases. J Mol Neurosci. 2017;61:379–84.

    CAS  PubMed  Google Scholar 

  155. 155.

    Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 2016;172:402–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  156. 156.

    Chen J, Alberts I, Li X. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders. Int J Dev Neurosci. 2014;35:35–41.

    PubMed  Google Scholar 

  157. 157.

    Huber KM, Klann E, Costa-Mattioli M, Zukin RS. Dysregulation of mammalian target of rapamycin signaling in mouse models of autism. J Neurosci. 2015;35:13836–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  158. 158.

    Gkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB, et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature. 2013;493:371–7.

    CAS  Google Scholar 

  159. 159.

    Morgan JT, Chana G, Abramson I, Semendeferi K, Courchesne E, Everall IP. Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res. 2012;1456:72–81.

    CAS  PubMed  Google Scholar 

  160. 160.

    Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474:380–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  161. 161.

    Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  162. 162.

    Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, et al. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014;4:e400.

    CAS  PubMed  PubMed Central  Google Scholar 

  163. 163.

    Laroni A, de Rosbo NK, Uccelli A. Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. Immunol Lett. 2015;168:183–90.

    CAS  PubMed  Google Scholar 

  164. 164.

    Naviaux JC, Wang L, Li K, Bright AT, Alaynick WA, Williams KR, et al. Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Mol Autism. 2015;6:1.

    PubMed  PubMed Central  Google Scholar 

  165. 165.

    Wong H, Hoeffer C Maternal IL-17A in autism. Exp Neurol. 2018;299:228–40.

  166. 166.

    Mattei D, Ivanov A, Ferrai C, Jordan P, Guneykaya D, Buonfiglioli A, et al. Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment. Transl Psychiatry. 2017;7:e1120.

    CAS  PubMed  PubMed Central  Google Scholar 

  167. 167.

    Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World J Biol Psychiatry. 2016;17:174–86.

    PubMed  Google Scholar 

  168. 168.

    Piven J, Elison JT, Zylka MJ. Toward a conceptual framework for early brain and behavior development in autism. Mol Psychiatry. 2017;22:1385–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  169. 169.

    Thomas MS, Davis R, Karmiloff-Smith A, Knowland VC, Charman T. The over-pruning hypothesis of autism. Dev Sci. 2016;19:284–305.

    PubMed  Google Scholar 

  170. 170.

    Johnson MH, Jones EJ, Gliga T. Brain adaptation and alternative developmental trajectories. Dev Psychopathol. 2015;27:425–42.

    PubMed  Google Scholar 

  171. 171.

    Johnson MH. Autism as an adaptive common variant pathway for human brain development. Dev Cogn Neurosci. 2017;25:5–11.

    PubMed  Google Scholar 

  172. 172.

    Waddington CH. Canalization of development and the inheritance of acquired characters. Nature. 1942;150:563–5.

    Google Scholar 

  173. 173.

    Cicchetti D, Blender JA. A multiple-levels-of-analysis perspective on resilience: implications for the developing brain, neural plasticity, and preventive interventions. Ann NY Acad Sci. 2006;1094:248–58.

    PubMed  Google Scholar 

  174. 174.

    Pierce K, Conant D, Hazin R, Stoner R, Desmond J. Preference for geometric patterns early in life as a risk factor for autism. Arch Gen Psychiatry. 2011;68:101–9.

    PubMed  Google Scholar 

  175. 175.

    Pierce K, Marinero S, Hazin R, McKenna B, Barnes CC, Malige A. Eye tracking reveals abnormal visual preference for geometric images as an early biomarker of an autism spectrum disorder subtype associated with increased symptom severity. Biol Psychiatry. 2016;79:657–66.

    PubMed  Google Scholar 

  176. 176.

    Jones W, Klin A. Attention to eyes is present but in decline in 2-6-month-old infants later diagnosed with autism. Nature. 2013;504:427–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  177. 177.

    Orosco LA, Ross AP, Cates SL, Scott SE, Wu D, Sohn J, et al. Loss of Wdfy3 in mice alters cerebral cortical neurogenesis reflecting aspects of the autism pathology. Nat Commun. 2014;5:4692.

    CAS  PubMed  PubMed Central  Google Scholar 

  178. 178.

    Bacon EC, Courchesne, E, Carter Barnes, C, Cha, D, Pence, S, Schreibman, L, Stahmer, AC, & Pierce, K Rethinking the idea of late ASD onset. Dev Psychopathol. 2017.

  179. 179.

    Pierce K, Carter C, Weinfeld M, Desmond J, Hazin R, Bjork R, et al. Detecting, studying, and treating autism early: the one-year well-baby check-up approach. J Pediatr. 2011;159:458–65. e451-456.

    PubMed  PubMed Central  Google Scholar 

  180. 180.

    Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F). Pediatrics. 2014;133:37–45.

    PubMed  PubMed Central  Google Scholar 

  181. 181.

    Pierce K, Courchesne E, Bacon E. To screen or not to screen universally for autism is not the question: why the task force got it wrong. J Pediatr. 2016;176:182–94.

    PubMed  PubMed Central  Google Scholar 

  182. 182.

    Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125.

    PubMed  Google Scholar 

  183. 183.

    Gompers AL, Su-Feher L, Ellegood J, Copping NA, Riyadh MA, Stradleigh TW, et al. Germline Chd8 haploinsufficiency alters brain development in mouse. Nature Neuroscience. 2017;20:1062–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  184. 184.

    Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci. 2005;25:11288–99.

    CAS  PubMed  Google Scholar 

  185. 185.

    Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol. 2010;70:304–22.

  186. 186.

    Rosso SB, Inestrosa NC. WNT signaling in neuronal maturation and synaptogenesis. Front Cell Neurosci. 2013;7:103

  187. 187.

    Zhang X, Zhu J, Yang G-Y, Wang Q-J, Qian L, Chen Y-M, et al. Dishevelled promotes axon differentiation by regulating atypical protein kinase C. Nature Cell Biology. 2007;9:743–54.

    CAS  PubMed  Google Scholar 

  188. 188.

    Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5:173–83.

    CAS  PubMed  Google Scholar 

  189. 189.

    Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. Nature. 2013;493:327–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  190. 190.

    Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007;8:101–13.

    CAS  PubMed  Google Scholar 

  191. 191.

    Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  192. 192.

    Sugathan A, Biagioli M, Golzio C, Erdin S, Blumenthal I, Manavalan P, et al. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. Proceedings of the National Academy of Sciences. 2014;111:E4468–E4477.

    CAS  Google Scholar 

  193. 193.

    Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell. 2014;158:263–276.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references


This work was supported by NIMH R01-MH110558 (E.C., N.E.L.), NIMH R01-MH080134 (K.P.), NIMH R01-MH104446 (K.P.), Simons Foundation 176540 (E.C.), NFAR grant (K.P.), NIDCD R01-DC016385 (E.C., K.P., M.V.L.), NIMH R01-MH036840 (E.C.), NIMH U01-MH108898 (E.C.), CDMRP AR130409 (E.C.), NIGMS R35 GM119850 (N.E.L.), Brain and Behavior Research Foundation NARSAD (T.P.), and a European Research Council (ERC) Starting Grant (ERC-2017-STG 755816) (M.V.L.).

Author information



Corresponding author

Correspondence to Eric Courchesne.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Courchesne, E., Pramparo, T., Gazestani, V.H. et al. The ASD Living Biology: from cell proliferation to clinical phenotype. Mol Psychiatry 24, 88–107 (2019).

Download citation

Further reading


Quick links